Ryan A. Wilcox

Ryan A. Wilcox

Oncology | Hematology
1500 E Medical Center Dr
Floor B1 Reception A
Ann Arbor, MI 48109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 106 publications

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Journal: Blood
Published: April 30, 2026

A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.

A single-cell atlas identifies oncogenic transcriptional programs and immune escape mechanisms in CTCL.

Journal: Blood
Published: November 19, 2025

More than skin deep.

More than skin deep.

Journal: Blood
Published: October 02, 2025

CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas.

CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas.

Journal: Blood cancer journal
Published: August 29, 2025

Transcriptional Analysis of Effusion-Based Lymphoma Supports a Post-Germinal Center Origin and Specific Inflammatory Signal Background.

Transcriptional Analysis of Effusion-Based Lymphoma Supports a Post-Germinal Center Origin and Specific Inflammatory Signal Background.

Journal: Cancers
Published: August 20, 2025

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

Journal: Leukemia & lymphoma
Published: June 09, 2025

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.

Journal: American journal of hematology
Published: May 13, 2025

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Journal: Leukemia & lymphoma
Published: February 08, 2025

Understanding the Functional Dependence and Inhibition of the Bcl‑2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine.

Understanding the Functional Dependence and Inhibition of the Bcl‑2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine.

Journal: ACS pharmacology & translational science
Published: February 03, 2025

Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.

Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.

Journal: Blood
Published: November 14, 2024

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study.

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study.

Journal: Blood
Published: November 14, 2024

ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

Journal: Journal of the American Academy of Dermatology
Published: September 19, 2024
Showing 1-12 of 106

Last Updated: 09/26/2026